Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

  • End date
    Jan 31, 2024
  • participants needed
  • sponsor
    Institut de Recherches Internationales Servier
Updated on 1 May 2022
direct bilirubin
gilbert's syndrome
serum bilirubin level
acute promyelocytic leukemia


The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.

Condition Acute Myeloid Leukaemia
Treatment S 64315 (also referred as MIK665) and venetoclax
Clinical Study IdentifierNCT03672695
SponsorInstitut de Recherches Internationales Servier
Last Modified on1 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female aged ≥ 18 years
Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016), excluding acute promyelocytic leukaemia (APL, French-American British M3 classification)
With relapsed or refractory disease without established alternative therapy or
Secondary to MDS treated at least by hypomethylating agent and without established alternative therapy or
≥ 65 years not previously treated for AML and who are not candidates for intensive chemotherapy nor candidates for established alternative therapy
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Able to comply with study procedures
Adequate renal function within 7 days before the inclusion of the patient defined as
• Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine
clearance (determined by MDRD) > 50 mL/min/1.73m2
Adequate hepatic function within 7 days before the inclusion of the patient defined
AST and ALT ≤ 1.5 x ULN
Total serum bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN

Exclusion Criteria

Participant already enrolled and treated in the study
Pregnancy, breastfeeding or possibility of becoming pregnant during the study
Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP (participation in non-interventional registries or epidemiological studies is allowed). In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable
Presence of ≥ CTCAE Grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE, version 4.03)
Known carriers of HIV antibodies
Known history of significant liver disease
Uncontrolled hepatitis B or C infection
Known active acute or chronic pancreatitis
History of myocardial infarction (MI), unstable angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
Any factors that could increase the risk of QTc prolongation or risk of arrhythmic events
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note